ProShares Ultra NASDAQ Biotechnology
BIB
BIB
25 hedge funds and large institutions have $7.83M invested in ProShares Ultra NASDAQ Biotechnology in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 2 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more call options, than puts
Call options by funds: $ | Put options by funds: $
more funds holding
Funds holding: →
3.29% more ownership
Funds ownership: 3.85% → 7.14% (+3.3%)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Holders
25
Holding in Top 10
–
Calls
$2.14M
Puts
$1.46M
Top Buyers
| 1 | +$829K | |
| 2 | +$709K | |
| 3 | +$669K | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$545K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$332K |
Top Sellers
| 1 | -$1.53M | |
| 2 | -$72K | |
| 3 | -$17.6K | |
| 4 |
Morgan Stanley
New York
|
-$14.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$12.7K |